RxDoctor Payments DataLook up a doctor →

Charles Rose

Infectious Disease · Lexington, KYNPI 1568595874

Payments from drug & device makers

$170,987in general payments, 2019–2025

Across 733 payments — averaging $233.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$105K
  • Shionogi Inc$22K
  • La Jolla Pharmaceutical Company$18K
  • Viiv Healthcare Company$17K
  • Gilead$3K
  • Insmed, Inc.$1K
  • plus $5K from 19 others

What the payments were for

  • Speaking & faculty fees$46,68269%
  • Travel & lodging$4,4707%
  • Food & beverage$15,57523%
  • Education$1,0402%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$170,987 in reported general payments places this provider in the 90th percentile of 100 infectious disease providers in Kentucky.

See all infectious disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$347,910
Medicare patients
344
Services billed
114,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr13$204,289
DovatoDolutegravir Sodium/Lamivudine55$165,029
RukobiaFostemsavir Tromethamine11$87,652
BiktarvyBictegrav/Emtricit/Tenofov Ala16$62,849
JulucaDolutegravir/Rilpivirine11$44,381
Daptomycin36$37,939
CeftriaxoneCeftriaxone Sodium71$13,302
ErtapenemErtapenem Sodium13$8,633
Doxycycline Monohydrate273$8,247
Methenamine Hippurate116$7,916
Epinephrine32$7,343
Vancomycin Hcl46$5,462
Cephalexin201$4,503
Linezolid13$3,831
Cefepime Hcl17$3,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Rukobia, Juluca$16,928$297,06277 claims
Insmed, Inc.Arikayce$1,327$204,28913 claims
GileadBiktarvy$2,993$62,84916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 100 infectious disease providers in Kentucky.

Other infectious disease in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →